IP Library Granted Patent US 12,077,825
Granted Patent B2
US 12,077,825 · App. 17/849,982 · Granted Sep 3, 2024

Genetic polymorphisms associated with stroke, methods of detection and uses thereof

Inventors: May Luke (San Francisco, CA); James J. Devlin (Lafayette, CA)
Assignee: Celera Coporation
C12Q1/6883A61K31/22A61K31/35A61K31/40A61K31/404A61K31/435C12Q2600/118C12Q2600/156C12Q2600/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,077,825
App. No.
17/849,982
Granted
Sep 3, 2024
Kind
B2
Abstract

The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Claims (11)

1. A method for treating stroke in a human, the method comprising testing nucleic acid from said human for an MYH15 polymorphism rs3900940 comprising C at position 101 of SEQ ID NO:1213 or G at its complement, detecting a homozygous genotype of said C or said G to thereby identify said human as having an increased risk for stroke relative to not having said homozygous genotype, and administering a statin to treat stroke to said human.

2. The method of claim 1 , wherein said method comprises preparing a sample from said human that is enriched for a fragment of said nucleic acid that includes said position 101 of SEQ ID NO:1213 or its complement by amplifying said fragment by polymerase chain reaction (PCR).

3. The method of claim 1 , wherein said testing comprises amplifying by polymerase chain reaction (PCR) a fragment of said nucleic acid that includes said polymorphism rs3900940 to thereby create an amplicon containing said polymorphism rs3900940.

4. The method of claim 3 , wherein said testing comprises contacting said amplicon with an oligonucleotide that specifically hybridizes to said C or said G.

5. The method of claim 1 , wherein said testing comprises sequencing said nucleic acid.

6. The method of claim 1 , wherein said testing comprises contacting said nucleic acid with an oligonucleotide that specifically hybridizes to said C or said G.

7. The method of claim 6 , wherein the nucleotide sequence of said oligonucleotide consists of a segment within SEQ ID NO:1213, wherein the segment comprises at least 12 contiguous nucleotides of SEQ ID NO:1213 or its complement that includes said position 101.

8. The method of claim 6 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.

9. The method of claim 6 , wherein said oligonucleotide is an allele-specific probe.

10. The method of claim 6 , wherein said oligonucleotide is an allele-specific primer.

11. The method of claim 10 , wherein said allele-specific primer comprises the nucleotide sequence of SEQ ID NO:1873.

Continuity (7)
Division 16814085 · Mar 10, 2020
Continuation 15790581 · Oct 23, 2017
Continuation 14886595 · Oct 19, 2015
Continuation 13655905 · Oct 19, 2012
Continuation 12389313 · Feb 19, 2009
Provisional Application 61066584 · Feb 20, 2008
Related Publication 20230115835A1 · Apr 13, 2023